Latest News
-
Madrid, Spain – An off-label treatment with efgartigimod successfully helped manage severe, treatment-resistant Lambert-Eaton myasthenic syndrome (LEMS) in a 20-year-old woman in Spain whose disease had left her unable to walk independently or carry out basic daily activities. Following treatment, she regained significant mobility and independence, eventually becoming able to...
-
London, UK – GSK plc (LSE/NYSE: GSK) today announced that velzatinib, a novel, highly selective KIT inhibitor, has received Orphan Drug Designation (ODD) from Japan’s Ministry of Health Labour and Welfare for the treatment of gastrointestinal stromal tumour (GIST). The ODD was supported by data from the ongoing phase I/Ib...
-
TARRYTOWN, N.Y. — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Livsayis™ (cemdisiran) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive, the predominant form of the disease. Livsayis is a novel, complement component...
